Literature DB >> 17483967

Antitumor reactivity of non-metallocene titanium complexes of oxygen-based ligands: is ligand lability essential?

Michal Shavit1, Dani Peri, Artem Melman, Edit Y Tshuva.   

Abstract

In our attempt to define the parameters affecting anticancer activity of titanium complexes and to assess the role of hydrolytic stability, titanium compounds of oxygen-based ligands were studied. A homoleptic complex of hydroxyamino-1,3,5-triazine ligands was prepared and its hydrolysis was investigated by UV-vis spectroscopy at biologically relevant pH and temperature conditions based on its ligand to metal charge transfer absorption band. This complex exhibits very high hydrolytic stability under the conditions measured with negligible ligand dissociation. Its anticancer reactivity was investigated on ovarian OVCAR-1 and colon HT-29 cells, in comparison with the reference highly labile Ti(OiPr)(4) and TiCl(4)(THF)(2) (where THF is tetrahydrofuran), the inert thermodynamically stable TiO2, and the free aromatic hydroxyamino-1,3,5-triazine ligand. Whereas all reference titanium complexes were found to be completely unreactive against both tumor cell types, suggesting some moderate inertness is required, the homoleptic complex of the triazine ligands clearly possess some mild reactivity despite having no labile groups, and despite its incomplete solubility in the concentrations applied. As the free aromatic ligand is highly active under similar conditions, detailed time-dependence measurements were conducted and indicated that the cytotoxicity of the ligand is more affected by reducing incubation time, and that introducing the titanium complex to the medium prior to cell administration does not increase reactivity at a certain incubation time. These findings suggest that the reactivity of the complex does not result from that of the free ligand following dissociation, but rather involves the titanium center.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483967     DOI: 10.1007/s00775-007-0236-8

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  17 in total

1.  Synthesis, structure, and antitumor activity of a novel tetranuclear titanium complex.

Authors:  F Caruso; M Rossi; J Tanski; R Sartori; R Sariego; S Moya; S Diez; E Navarrete; A Cingolani; F Marchetti; C Pettinari
Journal:  J Med Chem       Date:  2000-10-05       Impact factor: 7.446

2.  Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.

Authors:  P Köpf-Maier
Journal:  Anticancer Res       Date:  1999 Jan-Feb       Impact factor: 2.480

3.  Stereoselective formation of seven-coordinate titanium(IV) monomer and dimer complexes of ethylenebis(o-hydroxyphenyl)glycine.

Authors:  M Guo; H Sun; S Bihari; J A Parkinson; R O Gould; S Parsons; P J Sadler
Journal:  Inorg Chem       Date:  2000-01-24       Impact factor: 5.165

4.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

5.  Distinctive structural features of hydroxyamino-1,3,5-triazine ligands leading to enhanced hydrolytic stability of their titanium complexes.

Authors:  Dani Peri; Jacob S Alexander; Edit Y Tshuva; Artem Melman
Journal:  Dalton Trans       Date:  2006-07-04       Impact factor: 4.390

Review 6.  Transferrin/transferrin receptor-mediated drug delivery.

Authors:  Hongyan Li; Zhong Ming Qian
Journal:  Med Res Rev       Date:  2002-05       Impact factor: 12.944

Review 7.  Titanium complexes in cancer treatment.

Authors:  Enrique Meléndez
Journal:  Crit Rev Oncol Hematol       Date:  2002-06       Impact factor: 6.312

Review 8.  Complexes of metals other than platinum as antitumour agents.

Authors:  P Köpf-Maier
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  Anti-proliferative activity and mechanism of action of titanocene dichloride.

Authors:  C V Christodoulou; A G Eliopoulos; L S Young; L Hodgkins; D R Ferry; D J Kerr
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

10.  Antitumour Metallocenes: Effect of DMSO on the Stability of Cp(2)TiX(2) and Implications for Anticancer Activity.

Authors:  G Mokdsi; M M Harding
Journal:  Met Based Drugs       Date:  1998
View more
  4 in total

1.  Cytotoxicity of a Ti(IV) compound is independent of serum proteins.

Authors:  Arthur D Tinoco; Horatio R Thomas; Christopher D Incarvito; Alan Saghatelian; Ann M Valentine
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-12       Impact factor: 11.205

2.  Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.

Authors:  Sergio A Loza-Rosas; Alexandra M Vázquez-Salgado; Kennett I Rivero; Lenny J Negrón; Yamixa Delgado; Josué A Benjamín-Rivera; Angel L Vázquez-Maldonado; Timothy B Parks; Charlene Munet-Colón; Arthur D Tinoco
Journal:  Inorg Chem       Date:  2017-06-23       Impact factor: 5.165

3.  Synthesis, spectral characterization, and antiproliferative studies of mixed ligand titanium complexes of adamantylamine.

Authors:  Raj Kaushal; Nitesh Kumar; Ashun Chaudhary; Saroj Arora; Pamita Awasthi
Journal:  Bioinorg Chem Appl       Date:  2014-02-27       Impact factor: 7.778

4.  Titanium Tackles the Endoplasmic Reticulum: A First Genomic Study on a Titanium Anticancer Metallodrug.

Authors:  Maya Miller; Anna Mellul; Maya Braun; Dana Sherill-Rofe; Emiliano Cohen; Zohar Shpilt; Irene Unterman; Ori Braitbard; Jacob Hochman; Edit Y Tshuva; Yuval Tabach
Journal:  iScience       Date:  2020-06-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.